ArticleFrontiers in oncology2021
Survival Analysis and Prediction Model for Pulmonary Sarcomatoid Carcinoma Based on SEER Database.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- A prediction model for 30-day mortality of sepsis patients based on intravenous fluids and electrolytes.Medicine · 2022Trial
- Nomogram and risk-score for predicting overall survival and risk stratification in patients with sarcomatoid non-small cell lung cancer: a multicenter study of 135 patients.BMC pulmonary medicine · 2025Article
- 3D‑printed template‑guided iodine‑125 seed implantation to treat complete occlusion of the superior vena cava in pulmonary sarcomatoid carcinoma: A case report.Oncology letters · 2024Article
- Survival analysis and nomogram for pulmonary sarcomatoid carcinoma: an SEER analysis and external validation.BMJ open · 2023Article
- Clinical outcomes of radical radiotherapy for pulmonary sarcomatoid carcinoma.Radiation oncology journal · 2023Article
- Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies.International journal of molecular sciences · 2023Article
- Demographics and Clinicopathologic Profile of Pulmonary Sarcomatoid Carcinoma with Survival Analysis and Genomic Landscape.Cancers · 2023Article
- Gastrointestinal bleeding due to jejunal metastasis of pleomorphic lung carcinoma: a case report.Annals of medicine and surgery (2012) · 2023Article
- Survival analysis and individualized prediction of survival benefit for pancreatic signet ring cell carcinoma: a population study based on the SEER database.BMC gastroenterology · 2023Article
- Individual risk and prognostic value prediction by machine learning for distant metastasis in pulmonary sarcomatoid carcinoma: a large cohort study based on the SEER database and the Chinese population.Frontiers in oncology · 2023Article
- An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFFrontiers in oncology · 2023Article
- Survival outcomes and prognostic factors of lung cancer patients with theFrontiers in oncology · 2023Article
- Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report.World journal of surgical oncology · 2022Article
- Development and validation of prediction model using nursing notes on sentiment scores for prognosis of patients with severe acute kidney injury receiving continuous renal replacement therapy based on computational intelligence algorithms.Annals of translational medicine · 2022Article
- Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report.Oncology letters · 2022Article
- Use of PD-1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report.Thoracic cancer · 2022Article
- Persistent fecal occult blood due to the small intestinal metastasis of pleomorphic lung carcinoma.Journal of surgical case reports · 2022Article
- Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art.Journal of oncology · 2022Review
- Prediction of readmission in patients with acute exacerbation of chronic obstructive pulmonary disease within one year after treatment and discharge.BMC pulmonary medicine · 2021Article
- The Prognosis of Pulmonary Sarcomatoid Carcinoma: Development and Validation of a Nomogram Based on SEER.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the incidence of the pulmonary sarcomatoid carcinoma (PSC), to compare the clinical characteristics and overall survival (OS) of patients with PSC and those with other non-small-cell lung cancer (oNSCLC), so as to analyze the factors affecting the OS of patients with PSC and construct a nomogram prediction model.
methodsData of patients with PSC and those with oNSCLC diagnosed between 2004 and 2015 from the Surveillance, Epidemiology, and End Results database were collected. The age-adjusted incidence of PSC was calculated. The characteristics of patients with PSC and those with oNSCLC were compared, then the patients were matched 1:2 for further survival analysis. Patients with PSC were randomly divided into training set and testing set with a ratio of 7:3. The Cox proportional hazards model was used to identify the covariates associated with the OS. Significant covariates were used to construct the nomogram, and the C-index was calculated to measure the discrimination ability. The accuracy of the nomogram was compared with the tumor-node-metastasis (TNM) clinical stage, and the corresponding area under the curve was achieved.
resultsA total of 1049 patients with PSC were enrolled, the incidence of PSC was slowly decreased from 0.120/100,000 in 2004 to 0.092/100,000 in 2015. Before PSM, 793 PSC patients and 191356 oNSCLC patients were identified, the proportion of male, younger patients (<65 years), grade IV, TNM clinical stage IV was higher in the PSC. The patients with PSC had significantly poorer OS compared with those with oNSCLC. After PSM, PSC still had an extremely inferior prognosis. Age, sex, TNM clinical stage, chemotherapy, radiotherapy, and surgery were independent factors for OS. Next, a nomogram was established based on these factors, and the C-indexs were 0.775 and 0.790 for the training and testing set, respectively. Moreover, the nomogram model indicated a more comprehensive and accurate prediction than the TNM clinical stage.
conclusionsThe incidence of PSC was slowly decreased. PSC had a significantly poor prognosis compared with oNSCLC. The nomogram constructed in this study accurately predicted the prognosis of PSC, performed better than the TNM clinical stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.